This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| SARS | 5143 |
| COVID-19 | 4729 |
| CoV-2 | 3325 |
| China | 1919 |
| el | 1625 |
| CoV | 988 |
| Wuhan | 971 |
| los | 954 |
| Coronavirus | 791 |
| con | 696 |
| MERS | 677 |
| para | 620 |
| del | 580 |
| un | 533 |
| RNA | 471 |
| las | 450 |
| Health | 443 |
| ACE2 | 441 |
| pacientes | 431 |
| una | 422 |
| CT | 420 |
| Disease | 401 |
| en | 389 |
| PCR | 342 |
| como | 303 |
| RT | 298 |
| por | 288 |
| Se | 280 |
| ARDS | 273 |
| es | 247 |
| Novel | 232 |
| uso | 215 |
| March | 213 |
| Italy | 208 |
| ICU | 207 |
| East | 204 |
| World | 195 |
| Middle | 195 |
| recomienda | 191 |
| Organization | 191 |
| remdesivir | 191 |
| Clinical | 190 |
| January | 188 |
| La | 183 |
| United | 180 |
| S | 180 |
| su | 175 |
| CoVs | 173 |
| States | 164 |
| IL-6 | 161 |
| ventilación | 147 |
| puede | 147 |
| December | 146 |
| ser | 137 |
| ritonavir | 137 |
| Remdesivir | 136 |
| WHO | 133 |
| Taiwan | 132 |
| Control | 130 |
| paciente | 128 |
| Syndrome | 127 |
| National | 124 |
| Hubei | 123 |
| lo | 122 |
| Respiratory | 122 |
| enfermedad | 121 |
| ECMO | 119 |
| Ebola | 119 |
| mg | 119 |
| diagnóstico | 116 |
| CDC | 116 |
| Prevention | 115 |
| February | 115 |
| AMCI | 115 |
| tratamiento | 114 |
| T | 113 |
| El | 113 |
| Chinese | 112 |
| Wang | 111 |
| Treatment | 111 |
| UCI | 111 |
| riesgo | 111 |
| estudio | 111 |
| más | 111 |
| estudios | 111 |
| meta | 108 |
| lopinavir | 108 |
| mortalidad | 107 |
| debe | 107 |
| New | 107 |
| se | 106 |
| Pneumonia | 105 |
| J | 105 |
| Covid-19 | 100 |
| April | 100 |
| Society | 100 |
| IgM | 100 |
| días | 99 |
| manejo | 98 |
| C | 95 |
| Transmission | 94 |
| Korea | 94 |
| Care | 94 |
| Fig | 93 |
| US | 93 |
| • | 93 |
| USA | 93 |
| Patients | 92 |
| Center | 92 |
| han | 91 |
| Kong | 90 |
| CI | 90 |
| entre | 89 |
| SDRA | 89 |
| HCoV | 89 |
| HCQ | 88 |
| IgG | 88 |
| India | 88 |
| sobre | 88 |
| RBD | 87 |
| Hong | 87 |
| mecánica | 86 |
| der | 86 |
| sospecha | 85 |
| casos | 85 |
| esta | 83 |
| Table | 83 |
| HIV | 81 |
| Los | 80 |
| mayor | 80 |
| pueden | 78 |
| Singapore | 77 |
| LPV | 77 |
| Hydroxychloroquine | 77 |
| este | 76 |
| alta | 76 |
| International | 76 |
| H1N1 | 76 |
| Germany | 75 |
| AKI | 75 |
| Li | 75 |
| pulmonar | 75 |
| Hospital | 74 |
| Chloroquine | 74 |
| intubación | 73 |
| día | 73 |
| Pandemic | 73 |
| II | 72 |
| IFN | 72 |
| respiratoria | 71 |
| infección | 71 |
| grupo | 71 |
| azithromycin | 71 |
| FDA | 70 |
| Chen | 70 |
| Province | 70 |
| cuidados | 70 |
| CoV-1 | 69 |
| South | 69 |
| sha | 68 |
| Group | 68 |
| hydroxychloroquine | 68 |
| Lopinavir | 68 |
| personal | 67 |
| fue | 66 |
| Europe | 66 |
| CFR | 66 |
| A | 66 |
| presión | 65 |
| clínico | 65 |
| von | 65 |
| Characteristics | 64 |
| Medical | 64 |
| tiempo | 63 |
| síntomas | 62 |
| evidencia | 62 |
| TMPRSS2 | 62 |
| PPE | 62 |
| France | 62 |
| Association | 62 |
| Review | 61 |
| Virus | 61 |
| lymphopenia | 61 |
| Study | 60 |
| Infection | 60 |
| clínica | 59 |
| UK | 59 |
| Medicine | 59 |
| tocilizumab | 58 |
| salud | 58 |
| menor | 58 |
| hasta | 58 |
| Japan | 58 |
| DOI | 58 |
| R0 | 57 |
| Report | 57 |
| son | 56 |
| N95 | 56 |
| Kenya | 56 |
| Epidemiology | 56 |
| Emergency | 56 |
| Coronaviruses | 56 |
| Analysis | 56 |
| soporte | 55 |
| horas | 55 |
| York | 55 |
| M | 55 |
| American | 54 |
| Human | 54 |
| Global | 54 |
| Las | 54 |
| Republic | 54 |
| Zhou | 54 |
| si | 54 |
| pero | 53 |
| pandemia | 53 |
| fueron | 53 |
| bajo | 53 |
| Trial | 53 |
| Liu | 53 |
| IC | 53 |
| COV-2 | 53 |
| People | 52 |
| CRISPR | 52 |
| City | 52 |
| CoV. | 52 |
| N | 52 |
| cuenta | 52 |
| Spain | 52 |
| University | 52 |
| Zhang | 52 |
| protección | 52 |
| Research | 51 |
| America | 51 |
| Committee | 51 |
| Commission | 51 |
| alto | 51 |
| cols | 51 |
| realizar | 51 |
| contra | 50 |
| Lancet | 50 |
| Infectious | 50 |
| α | 49 |
| respiratorio | 49 |
| nivel | 49 |
| Use | 49 |
| OC43 | 49 |
| L | 49 |
| Influenza | 49 |
| COVID | 48 |
| RdRp | 48 |
| und | 48 |
| dosis | 47 |
| deben | 47 |
| atención | 47 |
| Vero | 47 |
| Tocilizumab | 47 |
| Public | 47 |
| IV | 47 |
| Diseases | 47 |
| ACE-2 | 47 |
| clínicos | 46 |
| Detection | 46 |
| aguda | 46 |
| cual | 46 |
| inicio | 46 |
| severa | 46 |
| oxigenación | 45 |
| otros | 45 |
| compromiso | 45 |
| May | 45 |
| ELISA | 45 |
| Chest | 45 |
| Figure | 44 |
| Case | 44 |
| En | 44 |
| E | 44 |
| Science | 44 |
| intensivos | 44 |
| oxígeno | 44 |
| niveles | 43 |
| mejoría | 43 |
| cuales | 43 |
| críticos | 43 |
| Wu | 43 |
| Diagnosis | 43 |
| Huanan | 42 |
| CD4 | 42 |
| Cov-2 | 42 |
| D | 42 |
| resultados | 42 |
| terapia | 42 |
| NL63 | 42 |
| ® | 42 |
| vía | 42 |
| sido | 42 |
| número | 41 |
| State | 41 |
| S1 | 41 |
| LAMP | 41 |
| Cancer | 41 |
| severo | 40 |
| Institute | 40 |
| Ritonavir | 40 |
| bei | 40 |
| ya | 40 |
| tiene | 40 |
| tipo | 40 |
| todos | 40 |
| CD8 | 39 |
| Coronaviridae | 39 |
| coronavirus | 39 |
| CC | 39 |
| Arabia | 39 |
| Saudi | 39 |
| donde | 39 |
| seguridad | 39 |
| ingreso | 39 |
| neumonía | 39 |
| pronóstico | 39 |
| favipiravir | 39 |
| S2 | 38 |
| Development | 38 |
| Iran | 38 |
| Journal | 38 |
| Management | 38 |
| desde | 38 |
| dos | 38 |
| durante | 38 |
| estos | 38 |
| menos | 38 |
| recursos | 38 |
| utilizar | 38 |
| convaleciente | 37 |
| Angiotensin | 37 |
| Drug | 37 |
| Kawasaki | 37 |
| Por | 37 |
| Viral | 37 |
| decisiones | 37 |
| estrategia | 37 |
| manera | 37 |
| realización | 37 |
| recibieron | 37 |
| falla | 37 |
| momento | 36 |
| cuando | 36 |
| crítico | 36 |
| baja | 36 |
| así | 36 |
| IQR | 36 |
| HKU1 | 36 |
| European | 36 |
| EPP | 36 |
| July | 35 |
| General | 35 |
| Africa | 35 |
| Es | 35 |
| Team | 35 |
| RCT | 35 |
| BY | 35 |
| equipo | 35 |
| hipoxemia | 35 |
| medidas | 35 |
| mit | 35 |
| sugiere | 35 |
| flujo | 35 |
| Risk | 34 |
| CoV2 | 34 |
| EC | 34 |
| Favipiravir | 34 |
| NC | 34 |
| Outcomes | 34 |
| TCZ | 34 |
| TNF | 34 |
| condiciones | 34 |
| disease | 34 |
| kg | 34 |
| posición | 34 |
| vida | 34 |
| North | 33 |
| B | 33 |
| Brazil | 33 |
| CRP | 33 |
| Hospitalized | 33 |
| Intensive | 33 |
| Huang | 33 |
| Yang | 33 |
| diferentes | 33 |
| recomendaciones | 33 |
| severidad | 33 |
| sin | 33 |
| considerar | 33 |
| De | 32 |
| Centers | 32 |
| College | 32 |
| Convalescent | 32 |
| COVID-2019 | 32 |
| LV | 32 |
| necesario | 32 |
| reducción | 32 |
| criterios | 32 |
| infecciones | 31 |
| IVIG | 31 |
| PEEP | 31 |
| Response | 31 |
| disponibilidad | 31 |
| efectos | 31 |
| luego | 31 |
| lesión | 31 |
| multicentre | 31 |
| procedimiento | 31 |
| traslado | 31 |
| utilización | 31 |
| GGO | 31 |
| Distress | 30 |
| Impact | 30 |
| NIV | 30 |
| Canada | 30 |
| Administration | 30 |
| Lombardy | 30 |
| sea | 30 |
| estándar | 30 |
| nicht | 30 |
| recomendación | 30 |
| tanto | 30 |
| medRxiv | 30 |
| Guangdong | 29 |
| aerosoles | 29 |
| Princess | 29 |
| HIV-1 | 29 |
| HCoV-229E | 29 |
| Guidance | 29 |
| Critical | 29 |
| E6 | 29 |
| complicaciones | 29 |
| Chan | 29 |
| CNS | 29 |
| Asia | 29 |
| clínicas | 29 |
| Si | 29 |
| consentimiento | 29 |
| médico | 29 |
| también | 29 |
| control | 29 |
| solo | 29 |
| respuesta | 29 |
| plasma | 29 |
| síndrome | 29 |
| médica | 29 |
| ivermectin | 29 |
| hospitalaria | 29 |
| ensayos | 29 |
| einer | 29 |
| auch | 28 |
| Acute | 28 |
| Cardiac | 28 |
| Features | 28 |
| Guillain | 28 |
| S. | 28 |
| Tang | 28 |
| Therapy | 28 |
| U.S. | 28 |
| Una | 28 |
| algunos | 28 |
| M. | 28 |
| aérea | 28 |
| zu | 28 |
| cada | 28 |
| werden | 28 |
| sind | 28 |
| según | 28 |
| través | 28 |
| revisión | 28 |
| evaluar | 28 |
| disminución | 28 |
| decisión | 28 |
| MRI | 27 |
| Corona | 27 |
| Early | 27 |
| Evaluation | 27 |
| FUNDAMENTO | 27 |
| First | 27 |
| Kindern | 27 |
| TCM | 27 |
| ORF1ab | 27 |
| Taxonomy | 27 |
| asociada | 27 |
| elevación | 27 |
| evitar | 27 |
| información | 27 |
| sus | 27 |
| apoyo | 26 |
| Aerosol | 26 |
| Baricitinib | 26 |
| Immune | 26 |
| June | 26 |
| Plasma | 26 |
| Structure | 26 |
| System | 26 |
| análisis | 26 |
| qPCR | 26 |
| debido | 26 |
| está | 26 |
| importante | 26 |
| medicamentos | 26 |
| oseltamivir | 26 |
| tener | 26 |
| volumen | 26 |
| disminuir | 26 |
| Guidelines | 25 |
| NP | 25 |
| Ministry | 25 |
| Ill | 25 |
| Healthcare | 25 |
| Australia | 25 |
| Director | 25 |
| CRRT | 25 |
| Betacoronavirus | 25 |
| ARB | 25 |
| Spike | 25 |
| PaO2 | 25 |
| Lung | 25 |
| Viruses | 25 |
| parte | 25 |
| tomar | 25 |
| teniendo | 25 |
| servicios | 25 |
| sensibilidad | 25 |
| Washington | 25 |
| efecto | 25 |
| antes | 25 |
| trabajo | 25 |
| Xiao | 25 |
| aumento | 25 |
| Effect | 24 |
| R | 24 |
| Patient | 24 |
| Molecular | 24 |
| Meta | 24 |
| IGIV | 24 |
| Efficacy | 24 |
| Commons | 24 |
| Creative | 24 |
| Un | 24 |
| Children | 24 |
| Centre | 24 |
| CRS | 24 |
| Arbidol | 24 |
| < | 24 |
| ST | 24 |
| Receptor | 24 |
| punto | 24 |
| intensivo | 24 |
| viral | 24 |
| uno | 24 |
| tienen | 24 |
| asociado | 24 |
| muestras | 24 |
| ist | 24 |
| acuerdo | 24 |
| hallazgos | 24 |
| eventos | 24 |
| eine | 24 |
| den | 24 |
| dass | 24 |
| comité | 24 |
| beneficio | 24 |
| Assessment | 23 |
| Barré | 23 |
| Beijing | 23 |
| Data | 23 |
| I | 23 |
| Intelligence | 23 |
| Med | 23 |
| NIH | 23 |
| Rapid | 23 |
| anticuerpos | 23 |
| adversos | 23 |
| informado | 23 |
| muestra | 23 |
| presencia | 23 |
| renal | 23 |
| siendo | 23 |
| veces | 23 |
| zur | 23 |
| establecer | 23 |
| Dynamics | 22 |
| Para | 22 |
| Kingdom | 22 |
| Fuerte | 22 |
| Epidemiological | 22 |
| CVD | 22 |
| Diamond | 22 |
| DIC | 22 |
| Cardiovascular | 22 |
| RECOMENDACIÓN | 22 |
| CQ | 22 |
| Artificial | 22 |
| Phase | 22 |
| LDH | 22 |
| RR | 22 |
| hospitalizados | 22 |
| adultos | 22 |
| vivo | 22 |
| tratados | 22 |
| significativa | 22 |
| marzo | 22 |
| prueba | 22 |
| estrategias | 22 |
| escala | 22 |
| crítica | 22 |
| bronchoalveolar | 22 |
| auf | 22 |
| aire | 22 |
| Identification | 21 |
| Vaccine | 21 |
| carga | 21 |
| Thailand | 21 |
| Severe | 21 |
| PubMed | 21 |
| Outbreak | 21 |
| Antibody | 21 |
| Heart | 21 |
| Epidemic | 21 |
| Emerging | 21 |
| Department | 21 |
| B. | 21 |
| Azithromycin | 21 |
| ante | 21 |
| general | 21 |
| críticamente | 21 |
| objetivo | 21 |
| da | 21 |
| toma | 21 |
| sistema | 21 |
| siguientes | 21 |
| requiere | 21 |
| reanimación | 21 |
| sich | 21 |
| necesidad | 21 |
| nCOVID-19 | 21 |
| medición | 21 |
| invasiva | 21 |
| interleukin-6 | 21 |
| disease-2019 | 21 |
| Market | 20 |
| agudo | 20 |
| Zika | 20 |
| Sepsis | 20 |
| Sciences | 20 |
| STEMI | 20 |
| Recommendations | 20 |
| OMS | 20 |
| Adults | 20 |
| Infections | 20 |
| IL-10 | 20 |
| HFNC | 20 |
| Food | 20 |
| England | 20 |
| Cheng | 20 |
| Associated | 20 |
| covid-19 | 20 |
| calidad | 20 |
| chloroquine | 20 |
| sedación | 20 |
| mejor | 20 |
| tasa | 20 |
| curso | 20 |
| rutinaria | 20 |
| retrospectivo | 20 |
| residuos | 20 |
| otras | 20 |
| mid | 20 |
| presenta | 20 |
| grupos | 20 |
| gestión | 20 |
| función | 20 |
| frecuencia | 20 |
| fase | 20 |
| evolución | 20 |
| estado | 20 |
| enfermos | 20 |
| NK | 19 |
| aún | 19 |
| asociación | 19 |
| anakinra | 19 |
| adecuado | 19 |
| Seafood | 19 |
| Safety | 19 |
| RaTG13 | 19 |
| caso | 19 |
| NHC | 19 |
| Microbiology | 19 |
| JAK | 19 |
| IL-1 | 19 |
| HCV | 19 |
| Cross | 19 |
| COV | 19 |
| camas | 19 |
| muy | 19 |
| contexto | 19 |
| factores | 19 |
| rutina | 19 |
| cuanto | 19 |
| ningún | 19 |
| manifestaciones | 19 |
| fuera | 19 |
| frente | 19 |
| final | 19 |
| incluyendo | 19 |
| evaluaron | 19 |
| enfermo | 19 |
| dificultad | 19 |
| deterioro | 19 |
| desenlaces | 19 |
| dentro | 19 |
| demostrado | 19 |
| Surface | 18 |
| datos | 18 |
| contagio | 18 |
| central | 18 |
| cambios | 18 |
| Year | 18 |
| Yan | 18 |
| Xu | 18 |
| Union | 18 |
| Genomic | 18 |
| SpO2 | 18 |
| Maßnahmen | 18 |
| MV | 18 |
| Laboratory | 18 |
| Joint | 18 |
| Jan | 18 |
| Hu | 18 |
| Central | 18 |
| CBT | 18 |
| duración | 18 |
| disponible | 18 |
| nur | 18 |
| edad | 18 |
| protocolo | 18 |
| elementos | 18 |
| unidades | 18 |
| todo | 18 |
| sistemática | 18 |
| significativamente | 18 |
| retiro | 18 |
| reportaron | 18 |
| pruebas | 18 |
| protocolos | 18 |
| requieren | 18 |
| proceso | 18 |
| presentaron | 18 |
| perfusión | 18 |
| hospitalización | 18 |
| genera | 18 |
| están | 18 |
| esto | 18 |
| prevención | 18 |
| enfermedades | 18 |
| November | 17 |
| Isolation | 17 |
| Lu | 17 |
| Network | 17 |
| Time | 17 |
| Origin | 17 |
| Systematic | 17 |
| Imaging | 17 |
| Interim | 17 |
| ACS | 17 |
| Genome | 17 |
| G | 17 |
| Fälle | 17 |
| Expert | 17 |
| Esta | 17 |
| Effectiveness | 17 |
| Cell | 17 |
| CECC | 17 |
| Bat | 17 |
| adecuada | 17 |
| Yu | 17 |
| PLpro | 17 |
| ageusia | 17 |
| humano | 17 |
| als | 17 |
| γ | 17 |
| términos | 17 |
| transmisión | 17 |
| riesgos | 17 |
| procesos | 17 |
| nucleocapsid | 17 |
| mediante | 17 |
| mRNA | 17 |
| seguimiento | 17 |
| ha | 17 |
| evaluación | 17 |
| después | 17 |
| daño | 17 |
| darunavir | 17 |
| cuadro | 17 |
| capacidad | 17 |
| extubación | 17 |
| aunque | 17 |
| ND | 16 |
| IL-6R | 16 |
| Inhibitors | 16 |
| Interleukin-6 | 16 |
| Investigation | 16 |
| MS | 16 |
| Radiology | 16 |
| Nature | 16 |
| Pediatric | 16 |
| RPA | 16 |
| Reviews | 16 |
| Rhinolophus | 16 |
| High | 16 |
| ID | 16 |
| COVID‐19 | 16 |
| H7N9 | 16 |
| GI | 16 |
| Foundation | 16 |
| Findings | 16 |
| EM | 16 |
| Discovery | 16 |
| Council | 16 |
| CSF | 16 |
| CRB-65 | 16 |
| Brugada | 16 |
| Academy | 16 |
| ACE | 16 |
| Social | 16 |
| Shenzhen | 16 |
| Antiviral | 16 |
| Support | 16 |
| implementación | 16 |
| Thoracic | 16 |
| wird | 16 |
| valoración | 16 |
| β | 16 |
| unidad | 16 |
| umifenovir | 16 |
| tórax | 16 |
| siempre | 16 |
| reducir | 16 |
| prono | 16 |
| probabilidad | 16 |
| posterior | 16 |
| intervenciones | 16 |
| trabajadores | 16 |
| herramienta | 16 |
| contaminación | 16 |
| fecha | 16 |
| Y | 16 |
| Zhejiang | 16 |
| alteraciones | 16 |
| cardiovasculares | 16 |
| complejidad | 16 |
| comparado | 16 |
| des | 16 |
| doc_id | 16 |
| east | 16 |
| ensayo | 16 |
| estancia | 16 |
| PD-1 | 15 |
| Ribavirin | 15 |
| Plan | 15 |
| Presymptomatic | 15 |
| Protein | 15 |
| QT | 15 |
| R. | 15 |
| además | 15 |
| Russia | 15 |
| Summary | 15 |
| VMNI | 15 |
| Zhao | 15 |
| Zhu | 15 |
| aber | 15 |
| Kinder | 15 |
| Lin | 15 |
| C. | 15 |
| JAMA | 15 |
| Incubation | 15 |
| III | 15 |
| HR | 15 |
| FiO2 | 15 |
| Feb | 15 |
| Esto | 15 |
| Epidemiologic | 15 |
| EVD | 15 |
| Dis | 15 |
| DNA | 15 |
| Community | 15 |
| CXR | 15 |
| CK | 15 |
| años | 15 |
| asociados | 15 |
| aplicación | 15 |
| bolsa | 15 |
| recurso | 15 |
| pH | 15 |
| población | 15 |
| presentan | 15 |
| primeras | 15 |
| primeros | 15 |
| realizaron | 15 |
| rendimiento | 15 |
| monitoreo | 15 |
| reportado | 15 |
| sanitario | 15 |
| situaciones | 15 |
| suficiente | 15 |
| tiempos | 15 |
| traqueostomía | 15 |
| otro | 15 |
| útil | 15 |
| mayo | 15 |
| hacer | 15 |
| manos | 15 |
| cardiovascular | 15 |
| emitir | 15 |
| entrenamiento | 15 |
| expertos | 15 |
| grave | 15 |
| específico | 15 |
| inicial | 15 |
| inmunoglobulina | 15 |
| insuficiencia | 15 |
| investigación | 15 |
| leve | 15 |
| lymphocytopenia | 15 |
| Reverse | 14 |
| MCS | 14 |
| Netherlands | 14 |
| ORF | 14 |
| Publicado | 14 |
| RV | 14 |
| Randomized | 14 |
| Umifenovir | 14 |
| Shanghai | 14 |
| Shi | 14 |
| Springer | 14 |
| Tabla | 14 |
| Testing | 14 |
| U | 14 |
| MAbs | 14 |
| MB | 14 |
| ECG | 14 |
| L. | 14 |
| Cai | 14 |
| Zhonghua | 14 |
| AIDS | 14 |
| Animal | 14 |
| Application | 14 |
| Breakthrough | 14 |
| C3 | 14 |
| Cochrane | 14 |
| J. | 14 |
| Dr. | 14 |
| Estos | 14 |
| GS-5734 | 14 |
| HLA | 14 |
| HR1 | 14 |
| Hopkins | 14 |
| Verlauf | 14 |
| tratamientos | 14 |
| aumentar | 14 |
| solución | 14 |
| ni | 14 |
| nutrición | 14 |
| personas | 14 |
| protein | 14 |
| pulmonares | 14 |
| rápida | 14 |
| temprana | 14 |
| médicos | 14 |
| tracto | 14 |
| valores | 14 |
| ventilatorio | 14 |
| vez | 14 |
| áreas | 14 |
| biomarcadores | 14 |
| múltiples | 14 |
| sarilumab | 14 |
| mostró | 14 |
| exposición | 14 |
| metas | 14 |
| condición | 14 |
| directa | 14 |
| enfermería | 14 |
| equipos | 14 |
| específicos | 14 |
| existe | 14 |
| hospital | 14 |
| intensivista | 14 |
| mascarilla | 14 |
| mayores | 14 |
| mental | 14 |
| cardiaca | 14 |
| Virology | 13 |
| Zhong | 13 |
| Yuan | 13 |
| Su | 13 |
| Surviving | 13 |
| basado | 13 |
| September | 13 |
| abril | 13 |
| demostró | 13 |
| bisher | 13 |
| características | 13 |
| citocinas | 13 |
| controles | 13 |
| coronaviruses | 13 |
| cánula | 13 |
| descrito | 13 |
| Potential | 13 |
| Region | 13 |
| Bangladesh | 13 |
| Pan | 13 |
| Corticosteroid | 13 |
| disfunción | 13 |
| Age | 13 |
| COPD | 13 |
| CPAP | 13 |
| Clin | 13 |
| Consensus | 13 |
| Contact | 13 |
| Cox | 13 |
| Mental | 13 |
| ELSO | 13 |
| Estimation | 13 |
| Gilead | 13 |
| Ivermectin | 13 |
| LMWH | 13 |
| Life | 13 |
| Lymphopenia | 13 |
| detección | 13 |
| escalas | 13 |
| disnea | 13 |
| protectora | 13 |
| oder | 13 |
| paro | 13 |
| participantes | 13 |
| posibilidad | 13 |
| primera | 13 |
| profesionales | 13 |
| progresión | 13 |
| respecto | 13 |
| noch | 13 |
| respirador | 13 |
| saturación | 13 |
| series | 13 |
| terapéutico | 13 |
| über | 13 |
| ≥ | 13 |
| einem | 13 |
| nuevo | 13 |
| quienes | 13 |
| nan | 13 |
| hay | 13 |
| moderado | 13 |
| endosomal | 13 |
| | 13 |
| estar | 13 |
| ello | 13 |
| fiebre | 13 |
| fármacos | 13 |
| esté | 13 |
| incluye | 13 |
| infectados | 13 |
| limitaciones | 13 |
| literatura | 13 |
| mesylate | 13 |
| incluidos | 13 |
| mmHg | 13 |
| Mission | 12 |
| Sierra | 12 |
| Studies | 12 |
| Strategies | 12 |
| Spread | 12 |
| Oxford | 12 |
| Rt | 12 |
| Preliminary | 12 |
| Multicenter | 12 |
| Sun | 12 |
| analysis | 12 |
| VTE | 12 |
| Vietnam | 12 |
| Working | 12 |
| Y. | 12 |
| Yao | 12 |
| Yin | 12 |
| alteración | 12 |
| aparición | 12 |
| aus | 12 |
| Johns | 12 |
| Leone | 12 |
| Belgium | 12 |
| Immunogenicity | 12 |
| Comparative | 12 |
| 8) | 12 |
| Ang | 12 |
| Anti | 12 |
| Bei | 12 |
| camostat | 12 |
| CCoV | 12 |
| COVID19 | 12 |
| Cases | 12 |
| Colombia | 12 |
| Concern | 12 |
| ICUs | 12 |
| Corporation | 12 |
| Cryo | 12 |
| Der | 12 |
| Erwachsenen | 12 |
| Este | 12 |
| Guan | 12 |
| H. | 12 |
| Humans | 12 |
| ICTV | 12 |
| beneficios | 12 |
| Times | 12 |
| capacitación | 12 |
| medida | 12 |
| negativos | 12 |
| nos | 12 |
| orotraqueal | 12 |
| pesar | 12 |
| positivo | 12 |
| procedimientos | 12 |
| qué | 12 |
| realiza | 12 |
| relación | 12 |
| resolución | 12 |
| respiratorias | 12 |
| sean | 12 |
| situación | 12 |
| supervivencia | 12 |
| tasas | 12 |
| todas | 12 |
| troponina | 12 |
| técnica | 12 |
| técnicas | 12 |
| | | 12 |
| catéter | 12 |
| negativa | 12 |
| signos | 12 |
| medicamento | 12 |
| ellos | 12 |
| china | 12 |
| marcadores | 12 |
| choque | 12 |
| cohorte | 12 |
| col | 12 |
| definir | 12 |
| diferencias | 12 |
| documento | 12 |
| durch | 12 |
| combinación | 12 |
| escenarios | 12 |
| experiencia | 12 |
| forma | 12 |
| gravedad | 12 |
| hace | 12 |
| inflamación | 12 |
| iniciar | 12 |
| institucional | 12 |
| línea | 12 |
| líquidos | 12 |
| PD | 11 |
| Program | 11 |
| Practice | 11 |
| Penn | 11 |
| PTSD | 11 |
| PT | 11 |
| NEWS-2 | 11 |
| Oseltamivir | 11 |
| Neurosurgery | 11 |
| Mechanisms | 11 |
| Mohamed | 11 |
| Medicina | 11 |
| Q | 11 |
| Protocol | 11 |
| W. | 11 |
| RAAS | 11 |
| RBM | 11 |
| RSV | 11 |
| SOC | 11 |
| San | 11 |
| Smith | 11 |
| Tx | 11 |
| Unit | 11 |
| Ventilation | 11 |
| Wei | 11 |
| West | 11 |
| acceso | 11 |
| adicional | 11 |
| Load | 11 |
| Long | 11 |
| Choornam | 11 |
| Letter | 11 |
| Deng | 11 |
| ALT | 11 |
| AST | 11 |
| Alphacoronavirus | 11 |
| Asymptomatic | 11 |
| Based | 11 |
| Bi | 11 |
| CPR | 11 |
| ClinicalTrials.gov | 11 |
| CoVZXC21 | 11 |
| Como | 11 |
| Corel | 11 |
| CorelDraw | 11 |
| Daten | 11 |
| altas | 11 |
| LFA | 11 |
| ECDC | 11 |
| Enzyme | 11 |
| Failure | 11 |
| G. | 11 |
| GM | 11 |
| H5N1 | 11 |
| HBPM | 11 |
| Impella | 11 |
| Interventions | 11 |
| Italia | 11 |
| JACC | 11 |
| Jing | 11 |
| KDIGO | 11 |
| admisión | 11 |
| Dong | 11 |
| anticoagulación | 11 |
| refractaria | 11 |
| miocárdica | 11 |
| multicéntrico | 11 |
| multiorgan | 11 |
| papel | 11 |
| patologías | 11 |
| permite | 11 |
| posible | 11 |
| presentación | 11 |
| primer | 11 |
| prona | 11 |
| práctica | 11 |
| puntos | 11 |
| recuperación | 11 |
| relacionadas | 11 |
| mejora | 11 |
| rápidamente | 11 |
| segura | 11 |
| sera | 11 |
| será | 11 |
| sistemas | 11 |
| sobrevida | 11 |
| temprano | 11 |
| tenían | 11 |
| transfusión | 11 |
| tuvieron | 11 |
| utilizados | 11 |
| ventilador | 11 |
| arbidol | 11 |
| middle | 11 |
| respiración | 11 |
| lugar | 11 |
| dispositivos | 11 |
| lograr | 11 |
| arritmias | 11 |
| aumenta | 11 |
| bioética | 11 |
| cardiaco | 11 |
| centro | 11 |
| comorbilidades | 11 |
| componentes | 11 |
| corona | 11 |
| coronavirus-2 | 11 |
| deberá | 11 |
| desarrollo | 11 |
| disponibles | 11 |
| confirmado | 11 |
| egreso | 11 |
| generales | 11 |
| le | 11 |
| impacto | 11 |
| identificar | 11 |
| https:// | 11 |
| hemodinámica | 11 |
| hacia | 11 |
| hidroxicloroquina | 11 |
| familia | 11 |
| esteroides | 11 |
| específica | 11 |
| eliminación | 11 |
| elevados | 11 |
| Note | 10 |
| MG | 10 |
| Non | 10 |
| Natural | 10 |
| NCBI | 10 |
| N. | 10 |
| Microbiol | 10 |
| MSC | 10 |
| Isothermal | 10 |
| Latin | 10 |
| LVEF | 10 |
| Kang | 10 |
| Kabasuraneer | 10 |
| Jiangxi | 10 |
| Interferon | 10 |
| Oncology | 10 |
| Nutrition | 10 |
| Sarbecovirus | 10 |
| One | 10 |
| Organ | 10 |
| Infected | 10 |
| Singh | 10 |
| Sars | 10 |
| SHERLOCK | 10 |
| SAS | 10 |
| SAR | 10 |
| RTV | 10 |
| Pulmonary | 10 |
| Pharmacologic | 10 |
| Period | 10 |
| Patienten | 10 |
| Pathogenesis | 10 |
| PaO | 10 |
| PUI | 10 |
| Organisation | 10 |
| Initial | 10 |
| Allergy | 10 |
| Immunity | 10 |
| IgA | 10 |
| Campaign | 10 |
| COVID-19-infected | 10 |
| COVID- | 10 |
| CID | 10 |
| Broad | 10 |
| Blood | 10 |
| BCoV | 10 |
| August | 10 |
| Attribution | 10 |
| Antibodies | 10 |
| Statement | 10 |
| Al | 10 |
| ADE | 10 |
| ACEI | 10 |
| ACC | 10 |
| Cas | 10 |
| Con | 10 |
| County | 10 |
| Gao | 10 |
| IP10 | 10 |
| Humoral | 10 |
| Hasta | 10 |
| Han | 10 |
| Graham | 10 |
| 10 | |
| GBS | 10 |
| DETECTR | 10 |
| Finalmente | 10 |
| Factors | 10 |
| FCoV | 10 |
| Erkrankungen | 10 |
| Entre | 10 |
| Daily | 10 |
| Stability | 10 |
| Personal | 10 |
| Surgeons | 10 |
| nitazoxanide | 10 |
| posibles | 10 |
| podrían | 10 |
| peso | 10 |
| parámetros | 10 |
| parainfluenza | 10 |
| paliativos | 10 |
| origen | 10 |
| necesarios | 10 |
| incluso | 10 |
| monitoria | 10 |
| modelos | 10 |
| methylprednisolone | 10 |
| marco | 10 |
| lactato | 10 |
| intervención | 10 |
| intensidad | 10 |
| posteriores | 10 |
| predecir | 10 |
| propone | 10 |
| puntaje | 10 |
| ≤ | 10 |
| Switzerland | 10 |
| óptimo | 10 |
| éticos | 10 |
| área | 10 |
| za | 10 |
| z. | 10 |
| wurde | 10 |
| virales | 10 |
| van | 10 |
| social | 10 |
| secuelas | 10 |
| respiradores | 10 |
| rel | 10 |
| quien | 10 |
| inferior | 10 |
| primero | 10 |
| incluir | 10 |
| beta-1b | 10 |
| asistencial | 10 |
| alguna | 10 |
| ajustar | 10 |
| aislamiento | 10 |
| adecuación | 10 |
| acerca | 10 |
| Yi | 10 |
| Workers | 10 |
| Wholesale | 10 |
| Wenzhou | 10 |
| 10 | |
| Verläufe | 10 |
| identificación | 10 |
| TGEV | 10 |
| Vaccines | 10 |
| asoció | 10 |
| aquellos | 10 |
| dímero | 10 |
| historia | 10 |
| hubo | 10 |
| guías | 10 |
| encuentra | 10 |
| encontraron | 10 |
| cadáver | 10 |
| diferencia | 10 |
| determinar | 10 |
| desinfectante | 10 |
| células | 10 |
| continuo | 10 |
| considera | 10 |
| consenso | 10 |
| comparación | 10 |
| hospitales | 10 |
| Pfefferbaum | 9 |
| Peng | 9 |
| Renin | 9 |
| Pre | 9 |
| Protective | 9 |
| Psychiatry | 9 |
| Renal | 9 |
| PRISMA | 9 |
| Pandemie | 9 |
| OD | 9 |
| PP | 9 |
| PHEIC | 9 |
| PCT | 9 |
| PAFI | 9 |
| Overview | 9 |
| Office | 9 |
| ORF8 | 9 |
| Sarilumab | 9 |
| Nowcasting | 9 |
| SARSr | 9 |
| Zheng | 9 |
| Seattle | 9 |
| Welfare | 9 |
| Ng | 9 |
| ausencia | 9 |
| alveolar | 9 |
| alerta | 9 |
| administración | 9 |
| Xiang | 9 |
| X | 9 |
| Wong | 9 |
| Waterman | 9 |
| SoC | 9 |
| Van | 9 |
| Transcription | 9 |
| Traditional | 9 |
| Toronto | 9 |
| Tian | 9 |
| Therapeutics | 9 |
| Technology | 9 |
| Surveillance | 9 |
| Nidovirales | 9 |
| Cardiology | 9 |
| Neurological | 9 |
| Diagnostic | 9 |
| FFP3 | 9 |
| F. | 9 |
| Epidemie | 9 |
| English | 9 |
| Eine | 9 |
| Education | 9 |
| ED | 9 |
| Digital | 9 |
| Dexamethasone | 9 |
| Neurologic | 9 |
| Delphi | 9 |
| CoV-2/ | 9 |
| Berlin | 9 |
| BMJ | 9 |
| Aunque | 9 |
| Amplification | 9 |
| Ahmed | 9 |
| bloqueo | 9 |
| Facility | 9 |
| Fan | 9 |
| GISAID | 9 |
| Grade | 9 |
| Nanjing | 9 |
| Mortality | 9 |
| Methodology | 9 |
| MCP1 | 9 |
| Letalität | 9 |
| Lau | 9 |
| Kumar | 9 |
| Jahren | 9 |
| Infizierten | 9 |
| Immunoglobulin | 9 |
| Iceland | 9 |
| IU | 9 |
| IP-10 | 9 |
| ID-19 | 9 |
| Ho | 9 |
| H | 9 |
| Guo | 9 |
| bis | 9 |
| observacional | 9 |
| brote | 9 |
| presentar | 9 |
| reportados | 9 |
| razonable | 9 |
| qSOFA | 9 |
| publicación | 9 |
| proteína | 9 |
| procalcitonina | 9 |
| principalmente | 9 |
| previamente | 9 |
| predictores | 9 |
| mostraron | 9 |
| positivos | 9 |
| plan | 9 |
| patología | 9 |
| ofrecer | 9 |
| novo | 9 |
| neurológicas | 9 |
| nervioso | 9 |
| necesaria | 9 |
| resistencia | 9 |
| sangre | 9 |
| segunda | 9 |
| significativo | 9 |
| cambio | 9 |
| último | 9 |
| índices | 9 |
| ésta | 9 |
| vital | 9 |
| unter | 9 |
| trombosis | 9 |
| tres | 9 |
| total | 9 |
| tormenta | 9 |
| tomografía | 9 |
| terapéutica | 9 |
| terapias | 9 |
| tenía | 9 |
| temperatura | 9 |
| sugieren | 9 |
| sintomatología | 9 |
| nacional | 9 |
| telesalud | 9 |
| moral | 9 |
| definida | 9 |
| espacio | 9 |
| ein | 9 |
| eficacia | 9 |
| efectividad | 9 |
| efectiva | 9 |
| difícil | 9 |
| dexametasona | 9 |
| desinfección | 9 |
| dados | 9 |
| espontánea | 9 |
| cuidado | 9 |
| controlado | 9 |
| continua | 9 |
| comunidad | 9 |
| compararon | 9 |
| claro | 9 |
| monitorización | 9 |
| citoquinas | 9 |
| especificidad | 9 |
| das | 9 |
| estas | 9 |
| implementar | 9 |
| mejorar | 9 |
| estén | 9 |
| medio | 9 |
| medicina | 9 |
| liberación | 9 |
| individuos | 9 |
| incremento | 9 |
| incidencia | 9 |
| kann | 9 |
| membrana | 9 |
| graves | 9 |
| grado | 9 |
| gasto | 9 |
| frecuente | 9 |
| huésped | 9 |
| formación | 9 |
| fenotipos | 9 |
| Park | 8 |
| OHNS | 8 |
| OR | 8 |
| Ontario | 8 |
| Open | 8 |
| Prem | 8 |
| Ping | 8 |
| Position | 8 |
| Pregnancy | 8 |
| Procalcitonin | 8 |
| Nursing | 8 |
| Population | 8 |
| Mao | 8 |
| Nitazoxanide | 8 |
| News | 8 |
| NLR | 8 |
| Milan | 8 |
| Mexico | 8 |
| Menschen | 8 |
| Mechanism | 8 |
| Manejo | 8 |
| MCP-1 | 8 |
| Luo | 8 |
| Publisher | 8 |
| Lunar | 8 |
| Protease | 8 |
| adecuadamente | 8 |
| RALE | 8 |
| Version | 8 |
| Liver | 8 |
| aspectos | 8 |
| antimaláricos | 8 |
| anterior | 8 |
| anosmia | 8 |
| agua | 8 |
| agentes | 8 |
| aa | 8 |
| Xuebijing | 8 |
| Women | 8 |
| Vitro | 8 |
| UTR | 8 |
| Radiological | 8 |
| Type | 8 |
| Transplant | 8 |
| TC | 8 |
| Síndrome | 8 |
| Sweden | 8 |
| Specimens | 8 |
| Situation | 8 |
| Sheahan | 8 |
| Series | 8 |
| Retrospective | 8 |
| Red | 8 |
| Loop | 8 |
| CPD | 8 |
| Liang | 8 |
| COVID-19-induced | 8 |
| Critically | 8 |
| Coronavirus-2 | 8 |
| Contamination | 8 |
| Comprehensive | 8 |
| CoV-2-specific | 8 |
| Cluster | 8 |
| Chu | 8 |
| Chang | 8 |
| Carrier | 8 |
| Cao | 8 |
| Camostat | 8 |
| Bioinformatics | 8 |
| DE | 8 |
| BTK | 8 |
| BCG | 8 |
| BAL | 8 |
| Authorization | 8 |
| AstraZeneca | 8 |
| Adult | 8 |
| Además | 8 |
| Activity | 8 |
| AP | 8 |
| ACV | 8 |
| bajos | 8 |
| Ct | 8 |
| DPP4 | 8 |
| Lee | 8 |
| HCWs | 8 |
| LVAD | 8 |
| Jean | 8 |
| Intravenous | 8 |
| Indian | 8 |
| ISTH | 8 |
| IL10 | 8 |
| IL-8 | 8 |
| IL-7 | 8 |
| Hung | 8 |
| Hunan | 8 |
| HR2 | 8 |
| Guideline | 8 |
| Darunavir | 8 |
| Guangzhou | 8 |
| Government | 8 |
| Gautret | 8 |
| Fang | 8 |
| Family | 8 |
| F | 8 |
| Equipment | 8 |
| Environmental | 8 |
| Entry | 8 |
| Embase | 8 |
| EU | 8 |
| azitromicina | 8 |
| principales | 8 |
| bioseguridad | 8 |
| optimizar | 8 |
| publicado | 8 |
| publicaciones | 8 |
| proporción | 8 |
| pronación | 8 |
| profunda | 8 |
| óxido | 8 |
| primario | 8 |
| prevenir | 8 |
| preoxigenación | 8 |
| paso | 8 |
| orgánica | 8 |
| obtener | 8 |
| pulmón | 8 |
| objetivos | 8 |
| nítrico | 8 |
| nucleoprotein | 8 |
| novel | 8 |
| negativas | 8 |
| mínimo | 8 |
| muestran | 8 |
| muerte | 8 |
| monocyte | 8 |
| moderada | 8 |
| modalidades | 8 |
| puedan | 8 |
| quirúrgica | 8 |
| medir | 8 |
| sólo | 8 |
| broncoscopia | 8 |
| índice | 8 |
| ética | 8 |
| zhi | 8 |
| xue | 8 |
| ventilados | 8 |
| vasculares | 8 |
| variabilidad | 8 |
| utilizado | 8 |
| utilidad | 8 |
| tolerancia | 8 |
| superior | 8 |
| realizarse | 8 |
| superficies | 8 |
| sowie | 8 |
| sospechoso | 8 |
| sobrevivientes | 8 |
| sobrecarga | 8 |
| siguiendo | 8 |
| serie | 8 |
| sehr | 8 |
| respectivamente | 8 |
| replicación | 8 |
| reciente | 8 |
| min | 8 |
| rhinorrhea | 8 |
| mecanismos | 8 |
| derechos | 8 |
| especiales | 8 |
| enero | 8 |
| encefalitis | 8 |
| eficiencia | 8 |
| dolor | 8 |
| documentado | 8 |
| disposición | 8 |
| disminuye | 8 |
| diciembre | 8 |
| diagnóstica | 8 |
| describieron | 8 |
| dar | 8 |
| específicas | 8 |
| correlación | 8 |
| contar | 8 |
| contacto | 8 |
| confirmados | 8 |
| colaboradores | 8 |
| cobicistat | 8 |
| cerebral | 8 |
| centros | 8 |
| causas | 8 |
| capilar | 8 |
| material | 8 |
| espectro | 8 |
| demanda | 8 |
| estructura | 8 |
| incluyeron | 8 |
| limpieza | 8 |
| estrés | 8 |
| limitada | 8 |
| laboratorio | 8 |
| isquémico | 8 |
| intravenosa | 8 |
| interferón | 8 |
| institucionales | 8 |
| iniciales | 8 |
| ingresados | 8 |
| inflamatorios | 8 |
| indirecta | 8 |
| intensivistas | 8 |
| frecuentes | 8 |
| gibt | 8 |
| falta | 8 |
| igual | 8 |
| fases | 8 |
| garantizar | 8 |
| evitando | 8 |
| group | 8 |
| haya | 8 |
| hemodinámico | 8 |
| hepatitis | 8 |
| Que | 7 |
| SD | 7 |
| RA | 7 |
| RASS | 7 |
| Recovery | 7 |
| Rep | 7 |
| Res | 7 |
| Services | 7 |
| Seroprevalence | 7 |
| SOFA | 7 |
| Scale | 7 |
| Según | 7 |
| Service | 7 |
| Settings | 7 |
| Quality | 7 |
| Quarantine | 7 |
| Neurosurgical | 7 |
| Pulmonar | 7 |
| PubChem | 7 |
| Profile | 7 |
| Polymerase | 7 |
| Persons | 7 |
| Perinatal | 7 |
| POCUS | 7 |
| PA | 7 |
| Observational | 7 |
| Northern | 7 |
| Nipah | 7 |
| Nations | 7 |
| Nanshan | 7 |
| Siddha | 7 |
| NT | 7 |
| Shen | 7 |
| aufgrund | 7 |
| Single | 7 |
| atípica | 7 |
| alternativa | 7 |
| altos | 7 |
| ampliamente | 7 |
| antivirales | 7 |
| artículos | 7 |
| ataque | 7 |
| autores | 7 |
| Solidarity | 7 |
| avanzada | 7 |
| base | 7 |
| bereits | 7 |
| betacoronavirus | 7 |
| bien | 7 |
| NICU | 7 |
| aleatorizados | 7 |
| actividades | 7 |
| acción | 7 |
| Zahl | 7 |
| VT | 7 |
| Upper | 7 |
| Turkey | 7 |
| Travel | 7 |
| Tongji | 7 |
| Tiwari | 7 |
| Tianjin | 7 |
| TEM | 7 |
| T. | 7 |
| Systems | 7 |
| Susceptibility | 7 |
| Stem | 7 |
| Spanish | 7 |
| NSAID | 7 |
| CEPI | 7 |
| NCP | 7 |
| DCC | 7 |
| Chronic | 7 |
| Citation | 7 |
| Cohort | 7 |
| Comorbidities | 7 |
| Crisis | 7 |
| Cui | 7 |
| Delhi | 7 |
| McGoogan | 7 |
| Design | 7 |
| Deutschland | 7 |
| Dr | 7 |
| Du | 7 |
| Dysregulation | 7 |
| Dímero | 7 |
| Chin | 7 |
| California | 7 |
| CTD | 7 |
| CO | 7 |
| cardiomyocyte | 7 |
| BiPAP | 7 |
| BMI | 7 |
| Antigenicity | 7 |
| Ante | 7 |
| Anosmia | 7 |
| Anakinra | 7 |
| Advanced | 7 |
| Access | 7 |
| AZ | 7 |
| ASAIO | 7 |
| APTT | 7 |
| AI | 7 |
| EUA | 7 |
| Echocardiography | 7 |
| Ein | 7 |
| Inhibitor | 7 |
| Maria | 7 |
| Mainland | 7 |
| Ling | 7 |
| Library | 7 |
| Lianhuaqingwen | 7 |
| Lai | 7 |
| King | 7 |
| KenyaCoV | 7 |
| K. | 7 |
| Jun | 7 |
| Italian | 7 |
| Int | 7 |
| Institutes | 7 |
| Initiative | 7 |
| Infektion | 7 |
| Ethics | 7 |
| Immunology | 7 |
| Hub | 7 |
| Host | 7 |
| Hel | 7 |
| Handbook | 7 |
| HCoVs | 7 |
| GenBank | 7 |
| GD | 7 |
| Function | 7 |
| Feng | 7 |
| Fc | 7 |
| Extracorporeal | 7 |
| Existe | 7 |
| Evolution | 7 |
| buena | 7 |
| Task | 7 |
| cefalea | 7 |
| neurosurgery | 7 |
| murieron | 7 |
| máscara | 7 |
| múltiple | 7 |
| nasofaríngeo | 7 |
| necesidades | 7 |
| neuromuscular | 7 |
| neurotropic | 7 |
| multiorgánica | 7 |
| paliativa | 7 |
| paliativo | 7 |
| pasiva | 7 |
| persistente | 7 |
| potencialmente | 7 |
| preocupación | 7 |
| mundial | 7 |
| modelo | 7 |
| inmune | 7 |
| lymphohistiocytosis | 7 |
| intubados | 7 |
| jedoch | 7 |
| lavado | 7 |
| lesiones | 7 |
| limitación | 7 |
| linfocitos | 7 |
| mL | 7 |
| ml | 7 |
| mascarillas | 7 |
| mencionados | 7 |
| menores | 7 |
| metaanálisis | 7 |
| metilprednisolona | 7 |
| mismo | 7 |
| presenten | 7 |
| principios | 7 |
| profilaxis | 7 |
| vor | 7 |
| tisular | 7 |
| trastornos | 7 |
| utilizando | 7 |
| valor | 7 |
| varias | 7 |
| vasopresor | 7 |
| welche | 7 |
| pulso | 7 |
| wie | 7 |
| 7 | |
| zona | 7 |
| ¼ | 7 |
| últimos | 7 |
| cercano | 7 |
| tabla | 7 |
| superioridad | 7 |
| superficie | 7 |
| sospechar | 7 |
| significativas | 7 |
| semana | 7 |
| secundarios | 7 |
| secundaria | 7 |
| sanitarios | 7 |
| sala | 7 |
| resultado | 7 |
| resonancia | 7 |
| relacionados | 7 |
| referencia | 7 |
| realizó | 7 |
| reacciones | 7 |
| pública | 7 |
| internacional | 7 |
| realizada | 7 |
| ingresan | 7 |
| dl | 7 |
| decidir | 7 |
| department | 7 |
| desafíos | 7 |
| desarrollaron | 7 |
| destete | 7 |
| dieser | 7 |
| doi | 7 |
| expansión | 7 |
| ecografía | 7 |
| einen | 7 |
| elección | 7 |
| epidemia | 7 |
| escasez | 7 |
| estadísticamente | 7 |
| corto | 7 |
| corriente | 7 |
| convencional | 7 |
| conocimiento | 7 |
| confusión | 7 |
| confirmación | 7 |
| comunicación | 7 |
| compliance | 7 |
| complemento | 7 |
| combinado | 7 |
| colocación | 7 |
| colchicine | 7 |
| coagulación | 7 |
| clasificación | 7 |
| cinco | 7 |
| inducido | 7 |
| cerebro | 7 |
| examen | 7 |
| corticoides | 7 |
| factor | 7 |
| hyperimmune | 7 |
| heparina | 7 |
| higiene | 7 |
| hiperinmune | 7 |
| hisopado | 7 |
| https://doi.org/10.1101/2020.04.09.20059865 | 7 |
| humanos | 7 |
| hypogeusia | 7 |
| habían | 7 |
| importin | 7 |
| incluyen | 7 |
| incluyó | 7 |
| falsos | 7 |
| indicaciones | 7 |
| indicación | 7 |
| haga | 7 |
| hospitalario | 7 |
| für | 7 |
| familiares | 7 |
| ferritina | 7 |
| fibrinógeno | 7 |
| fluidos | 7 |
| formas | 7 |
| fracaso | 7 |
| guiar | 7 |
| fenotipo | 7 |
| ganciclovir | 7 |
| generación | 7 |
| generador | 7 |
| getestet | 7 |
| global | 7 |
| Qian | 6 |
| Psychological | 6 |
| Scientific | 6 |
| Policy | 6 |
| Projection | 6 |
| Post | 6 |
| Relation | 6 |
| Pfizer | 6 |
| Registry | 6 |
| Sahin | 6 |
| Ren | 6 |
| Reproduction | 6 |
| Royal | 6 |
| Scr | 6 |
| Rp3-NP | 6 |
| Salud | 6 |
| Scopus | 6 |
| Pediatr | 6 |
| Pero | 6 |
| Material | 6 |
| Pangolin | 6 |
| PPV | 6 |
| MTHFDI | 6 |
| Madrid | 6 |
| Shock | 6 |
| Malayan | 6 |
| Malaysia | 6 |
| Mamera | 6 |
| Miller | 6 |
| Ministerio | 6 |
| Moderna | 6 |
| Mpro | 6 |
| NTD | 6 |
| Nepal | 6 |
| Nurses | 6 |
| Optimized | 6 |
| Organización | 6 |
| P | 6 |
| P. | 6 |
| Serologic | 6 |
| aplicar | 6 |
| Silva | 6 |
| Xia | 6 |
| adecuadas | 6 |
| ajustado | 6 |
| aleatorizado | 6 |
| algunas | 6 |
| alguno | 6 |
| ambos | 6 |
| amplio | 6 |
| anti | 6 |
| antibody | 6 |
| appendix | 6 |
| author(s | 6 |
| bacteriana | 6 |
| baricitinib | 6 |
| basada | 6 |
| bing | 6 |
| broadspectrum | 6 |
| MAS | 6 |
| Xue | 6 |
| XBJ | 6 |
| Specimen | 6 |
| Wit | 6 |
| Step | 6 |
| Stroke | 6 |
| Studie | 6 |
| TMPRSS | 6 |
| Tao | 6 |
| Therapies | 6 |
| Treatments | 6 |
| Troponin | 6 |
| U.K. | 6 |
| UEL | 6 |
| Ultrasound | 6 |
| VV | 6 |
| Validation | 6 |
| Veterinary | 6 |
| WBC | 6 |
| Wales | 6 |
| Wilder | 6 |
| MI | 6 |
| Aldosterone | 6 |
| MAPK | 6 |
| Blockers | 6 |
| CAP | 6 |
| COVID-19)-China | 6 |
| CPT | 6 |
| Cardiol | 6 |
| Cas12a | 6 |
| Chongqing | 6 |
| CitNetExplorer | 6 |
| Coagulopathy | 6 |
| Collaboration | 6 |
| Command | 6 |
| Common | 6 |
| Comparison | 6 |
| Correlation | 6 |
| Corticosteroids | 6 |
| Cuando | 6 |
| D. | 6 |
| Deltacoronavirus | 6 |
| Brain | 6 |
| BNP | 6 |
| Ländern | 6 |
| Assays | 6 |
| cabecera | 6 |
| AAK1 | 6 |
| AAP | 6 |
| ABO | 6 |
| ACHD | 6 |
| ADAM17 | 6 |
| ASRM | 6 |
| AT1R | 6 |
| AUC | 6 |
| Activation | 6 |
| Actualmente | 6 |
| Air | 6 |
| Airway | 6 |
| Americans | 6 |
| Anteil | 6 |
| Arbeit | 6 |
| Area | 6 |
| Dosing | 6 |
| Duan | 6 |
| EIA | 6 |
| EPOC | 6 |
| Intervention | 6 |
| IoT | 6 |
| JAK2 | 6 |
| Janus | 6 |
| Ji | 6 |
| Jiang | 6 |
| Jie | 6 |
| K | 6 |
| Kaletra | 6 |
| Kaplan | 6 |
| Kidney | 6 |
| Kim | 6 |
| LTEC | 6 |
| LUS | 6 |
| LVEDV | 6 |
| Leung | 6 |
| Lockdown | 6 |
| Intensiva | 6 |
| Imperial | 6 |
| IRA | 6 |
| GCSF | 6 |
| ER | 6 |
| Edition | 6 |
| Engineering | 6 |
| España | 6 |
| Fisher | 6 |
| Force | 6 |
| Fung | 6 |
| Guardian | 6 |
| IL2 | 6 |
| Guide | 6 |
| HL | 6 |
| HSM | 6 |
| HTS | 6 |
| Henan | 6 |
| Holshue | 6 |
| I. | 6 |
| bronchograms | 6 |
| linfopenia | 6 |
| carolacton | 6 |
| porque | 6 |
| predicción | 6 |
| presentó | 6 |
| presiones | 6 |
| previo | 6 |
| producir | 6 |
| profesional | 6 |
| promover | 6 |
| publicaron | 6 |
| pueda | 6 |
| radiografía | 6 |
| razón | 6 |
| realizado | 6 |
| reclutamiento | 6 |
| refiere | 6 |
| rehabilitación | 6 |
| relacionado | 6 |
| reporte | 6 |
| positiva | 6 |
| podrá | 6 |
| requerimiento | 6 |
| poder | 6 |
| nasales | 6 |
| necesitan | 6 |
| neurológicos | 6 |
| norepinefrina | 6 |
| nueva | 6 |
| nutricional | 6 |
| núcleo | 6 |
| observado | 6 |
| orden | 6 |
| orientar | 6 |
| oxigenoterapia | 6 |
| perfil | 6 |
| permita | 6 |
| placebo | 6 |
| plantea | 6 |
| plazo | 6 |
| pocos | 6 |
| reportes | 6 |
| requerimientos | 6 |
| máximo | 6 |
| tuvo | 6 |
| utilizarse | 6 |
| varios | 6 |
| vasopresina | 6 |
| vasopresores | 6 |
| venosa | 6 |
| ventaja | 6 |
| ventilatoria | 6 |
| vista | 6 |
| waren | 6 |
| weiteren | 6 |
| weltweit | 6 |
| zeigt | 6 |
| zum | 6 |
| zwischen | 6 |
| éxito | 6 |
| celulosa | 6 |
| − | 6 |
| usar | 6 |
| tratar | 6 |
| requirieron | 6 |
| tras | 6 |
| reserva | 6 |
| retrospectiva | 6 |
| rhesus | 6 |
| ribavirin | 6 |
| schweren | 6 |
| secundario | 6 |
| severas | 6 |
| sollte | 6 |
| suplementario | 6 |
| séptico | 6 |
| talento | 6 |
| temporal | 6 |
| tenga | 6 |
| tercera | 6 |
| thymosin | 6 |
| tos | 6 |
| totalidad | 6 |
| médicas | 6 |
| titulación | 6 |
| máscaras | 6 |
| desaturación | 6 |
| desenlace | 6 |
| desinfectar | 6 |
| directrices | 6 |
| distribución | 6 |
| diálisis | 6 |
| ebola | 6 |
| ecocardiografía | 6 |
| efectivo | 6 |
| elastoméricos | 6 |
| elevado | 6 |
| embarazadas | 6 |
| enfoque | 6 |
| enteral | 6 |
| epilépticas | 6 |
| ese | 6 |
| esfuerzo | 6 |
| estaban | 6 |
| describen | 6 |
| derecho | 6 |
| establece | 6 |
| dem | 6 |
| circuito | 6 |
| circunstancias | 6 |
| mundo | 6 |
| ciudad | 6 |
| clara | 6 |
| coagulopatía | 6 |
| compasivo | 6 |
| completa | 6 |
| comunes | 6 |
| conciencia | 6 |
| considerado | 6 |
| considerados | 6 |
| contrario | 6 |
| corte | 6 |
| cremación | 6 |
| cuadros | 6 |
| definitivo | 6 |
| estabilidad | 6 |
| convulsiones | 6 |
| establecido | 6 |
| inhalado | 6 |
| integral | 6 |
| interdependencia | 6 |
| interna | 6 |
| keine | 6 |
| legal | 6 |
| limitar | 6 |
| mTOR | 6 |
| manipulación | 6 |
| meses | 6 |
| miocarditis | 6 |
| modo | 6 |
| molecular | 6 |
| momentan | 6 |
| muerto | 6 |
| establecidos | 6 |
| muertes | 6 |
| morbilidad | 6 |
| inhibir | 6 |
| mejoraron | 6 |
| inflamatorias | 6 |
| hipoxia | 6 |
| gastrointestinales | 6 |
| fracción | 6 |
| incluya | 6 |
| generan | 6 |
| excepto | 6 |
| generar | 6 |
| 6 | |
| hipertensión | 6 |
| hipotensión | 6 |
| health | 6 |
| imagenológicos | 6 |
| importantes | 6 |
| imágenes | 6 |
| idealmente | 6 |
| identificó | 6 |
| https | 6 |
| Qing | 5 |
| Paulo | 5 |
| Puede | 5 |
| Propofol | 5 |
| Philadelphia | 5 |
| Prevalence | 5 |
| Prediction | 5 |
| Positive | 5 |
| Peninsula | 5 |
| REDLARA | 5 |
| Pennsylvania | 5 |
| RCP | 5 |
| Resource | 5 |
| RNAdependent | 5 |
| Radiographic | 5 |
| Radix | 5 |
| Recomendaciones | 5 |
| Regulations | 5 |
| Resonance | 5 |
| Return | 5 |
| Ribavirina | 5 |
| Roles | 5 |
| Rothe | 5 |
| PTL | 5 |
| SADS | 5 |
| SARS- | 5 |
| SDS | 5 |
| Parenteral | 5 |
| Neurology | 5 |
| PNS | 5 |
| Newborn | 5 |
| Meier | 5 |
| SVRI | 5 |
| Mechanical | 5 |
| Meng | 5 |
| Microfluidic | 5 |
| Municipal | 5 |
| NCT04257656 | 5 |
| NHCC | 5 |
| NTS | 5 |
| NY | 5 |
| Nasopharyngeal | 5 |
| Neck | 5 |
| Neonatal | 5 |
| Novo | 5 |
| PBPK | 5 |
| ONi | 5 |
| ORF1a | 5 |
| ORF1b | 5 |
| ORF3b | 5 |
| ORFs | 5 |
| Official | 5 |
| Olfactory | 5 |
| Online | 5 |
| Options | 5 |
| Orthocoronavirinae | 5 |
| Otras | 5 |
| Otro | 5 |
| P2 | 5 |
| SSD | 5 |